Regulatory T cells and tumour immunity - observations in mice and men.
about
Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancerSafety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parametersRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionEZH2 as a mediator of treatment resistance in melanomaImmunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity.Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cells via blood vessels and lymphatics.Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma.Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growthCharacterizing the glycome of the mammalian immune system.Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cellsClinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.Discovery of small molecule inhibitors to Krüppel-like factor 10 (KLF10): implications for modulation of T regulatory cell differentiationmicroRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells.CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.Regulatory T Cells in Melanoma Revisited by a Computational Clustering of FOXP3+ T Cell Subpopulations.Effects of CpG Oligodeoxynucleotide 1826 on transforming growth factor-beta 1 and radiation-induced pulmonary fibrosis in miceThe Immune Landscapes of Polypoid and Nonpolypoid Precancerous Colorectal LesionsEnhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck.DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.Cancer, aging and immunotherapy: lessons learned from animal models.Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells.Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.Immune microenvironmental shift along human colorectal adenoma-carcinoma sequence: is it relevant to tumor development, biomarkers and biotherapeutic targets?Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report.T regulatory cell mediated immunotherapy for solid organ transplantation: A clinical perspective.Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.Novel role of regulatory T cells in limiting early neutrophil responses in skin.Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma.Regulatory T cells in the past and for the future.Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion.Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma.
P2860
Q21089654-3DFDB4FE-64C3-48EA-B17C-35D0CB5D564EQ27002602-CA996A3B-A94E-48E3-97E9-3C3D607185CFQ28067145-ECA84D72-73FD-49A1-9173-50C4F64754D8Q28074492-AE98015C-E8AA-49EA-BC3E-D21DBF3BA6C2Q33393451-98C46F5E-1E93-4050-9B26-50212BE68305Q33638975-48E6C1E1-BB5B-478A-9DBF-A29D39040924Q33912224-1A03A4B0-DC6B-4AAC-89F6-631396458F33Q33967185-2717E129-DE7F-4E6E-AB41-83A20F01F9D1Q34041661-71B49A7B-7FBE-439C-870B-856E19B7C965Q34289902-709C2A29-3616-414D-A2D7-789778C07838Q34813256-0BEAB2EA-BE7F-4E8F-9D32-4BC764442C93Q35020804-C7DE9B0D-2EF5-44B2-AF19-2A43C9DF49BFQ35208161-D5706EB3-4EED-4804-B12F-2A5ED461BE04Q35541538-6F190387-63D0-44B8-95D6-AF7163E6E35EQ35597356-FEAEC115-3B86-4C5E-BCFB-EDC675C227B9Q36082118-9FAA4323-3830-45BB-BC0E-1A4C648205A7Q36498366-9EEDE729-A062-447E-B90B-2A393210C701Q36617341-95890152-C8ED-4304-9C32-1530B309B214Q36650596-72F8ACEF-B719-47F8-BDD3-48A78965CE7AQ36907395-AFBAC76D-F1A0-465A-8AB7-3A89E484F3DDQ37115232-E4CD7A2C-4B4F-4201-832D-4347B5931919Q37129671-B321565D-7525-4A82-9C65-1883B2F5BC6CQ37273138-335B28DE-C332-48B7-A4DE-9BB8AEBB826CQ37302327-72F3C1D9-BBEE-437C-8858-B35480544C6BQ37334966-7B840064-BAB0-4B3A-8E57-DDAC9D89FDB6Q37395354-4728FC91-C820-423C-B60C-2366FC1DBA0FQ37399946-BCCC0DEC-B990-4C57-8BFC-D044F6DFD426Q37597429-4381350A-19EF-40C9-A1CC-7401769D7146Q37604627-0C23EB17-6DE7-4350-B387-87E094A0B7ACQ37635491-CC8E2996-81C3-4824-A3E8-2223B7CFF401Q37974301-BEA44AEF-408D-49C5-ACC0-A6F2343C991DQ38345817-4AF37116-33B5-4A97-B922-839CE7621867Q39017604-F0744142-F739-44C7-96B3-54B1D28BB1EFQ39413297-2EF0FE34-E297-4F05-A8A7-B25A31533643Q39665724-B36CFB2F-A27F-4D01-8FF3-2B4F245992A4Q39853193-B77AACE9-E86A-4A68-8801-E0D6A1CC3F9AQ40105422-390935F7-4C34-470C-8DF3-D8830563FD62Q40355993-8E1416E5-B0E8-4167-8682-4D2989E491DDQ41400520-B205B851-D7DC-445D-B74A-CA7667D76B24Q43052209-A40058BC-DFD7-46A3-B8AD-FA051FDE52B3
P2860
Regulatory T cells and tumour immunity - observations in mice and men.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regulatory T cells and tumour immunity - observations in mice and men.
@en
Regulatory T cells and tumour immunity - observations in mice and men.
@nl
type
label
Regulatory T cells and tumour immunity - observations in mice and men.
@en
Regulatory T cells and tumour immunity - observations in mice and men.
@nl
prefLabel
Regulatory T cells and tumour immunity - observations in mice and men.
@en
Regulatory T cells and tumour immunity - observations in mice and men.
@nl
P2860
P1433
P1476
Regulatory T cells and tumour immunity - observations in mice and men
@en
P2093
Andrew Godkin
P2860
P304
P356
10.1111/J.1365-2567.2007.02748.X
P577
2007-12-07T00:00:00Z